Antibodies and Vaccines as Drugs for COVID-19 - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): David P. Humphreys, Pierre Bruhns, Patrick C. Wilson and Esther Breij Date: January 13 - 14, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
For important information on the coronavirus, please click here
COVID-19 has brought unprecedented society level attention on a truly global scale into antibody and vaccine science and technology. Billions of people are now aware of antibodies, therapeutic, protective and diagnostic and vaccine design, manufacturing and clinical trial design. On a medical level, COVID-19 has impacted every single country on the planet with currently 68 million confirmed infections and 1.5 million deaths. These numbers will continue to increase until natural immunity, improved therapeutic interventions, vaccines or a combination of all three succeed. Vaccines are a reality – clinical administration has started. Interventional antibodies are in late stage trials. This COVID event is simply the biggest medical and economic threat in modern history and antibody and vaccine science is at its core. This conference will bring together in an accessible on-line format key influencers and scientific advances from around the world and unite the scientific community in the first steps of defeating COVID-19. Keystone is unable to host its “Antibodies as Drugs” meeting as planned in January 2021 but will be replaced in part in a smaller COVID focused on-line meeting called “Antibodies and Vaccines as Drugs for COVID-19”. The meeting will have two 2½ hour on-line sessions, timed to fit in with most major time zones, each comprised of nine x 10 minutes invited oral presentations. One session will have a dedicated therapeutic antibody focus the other will have a vaccine focus. An on-line poster session is planned. Join the meeting to find out the very latest about COVID-19 therapeutic developments.
Scholarship Deadline: November 1 2020
We gratefully acknowledge additional support for this conference from: